Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJSQEF)

DTT Name Tyrosine-protein kinase (PTK)
Synonyms Protein-tyrosine kinase; PTK
Gene Name PTK
DTT Type
Successful target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T43415

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abrocitinib DM8J29L Atopic dermatitis EA80 Approved [2]
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [1]
------------------------------------------------------------------------------------
6 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [3]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [4]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [2]
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [4]
LEO 124249 DM7W0JE Asthma CA23 Phase 2 [2]
TD-1473 DMJG7AY Ulcerative colitis DD71 Phase 1 [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
8 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [5]
Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ N. A. N. A. Patented [5]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [5]
PMID27774822-Compound-Figure10CompoundA DM3M6SE N. A. N. A. Patented [6]
PMID27774822-Compound-Figure10Example1 DMCTXPQ N. A. N. A. Patented [6]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [5]
Ruxolitinib derivative 1 DM41ZW9 N. A. N. A. Patented [5]
Tetra-cyclic compound 1 DMS1GJD N. A. N. A. Patented [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Patented Agent(s)
4 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
SDZ-LAP-977 DMX4938 Psoriasis vulgaris EA90 Discontinued in Phase 2 [7]
PN-355 DMFKC7L Human immunodeficiency virus-1 infection 1C62 Discontinued in Phase 1 [8]
AP-23588 DMXLJBA Osteoporosis FB83.0 Terminated [9]
CLX-0301 DMVUL4P Diabetic complication 5A2Y Terminated [10]
------------------------------------------------------------------------------------

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
6 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
7 Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications. Bioorg Med Chem. 2008 Aug 15;16(16):7552-60.
8 WO patent application no. 2005,0502,03, Biological materials and uses thereof.
9 Foye's Principles of Medicinal Chemistry, Thomas L. Lemke, David A. Williams. 2008. Page(950).
10 CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3.